William Blair Estimates Ikena Oncology FY2029 Earnings
William Blair analysts have projected Ikena Oncology's FY2029 earnings per share (EPS) at ($5.41), significantly lower than the current consensus estimate of ($0.91). Additionally, Wedbush has reduced its price target for Ikena Oncology from $25.00 to $23.00, maintaining a "neutral" rating. The stock opened at $17.90, with a market cap of $71.96 million. Recent insider transactions include significant share purchases by Directors David P. Bonita and Otello Stampacchia, increasing their holdings substantially.
Ikena Oncology, Inc. (NASDAQ:IMA - Free Report) - Research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Ikena Oncology in a report issued on Wednesday, July 30th. William Blair analyst M. Phipps expects that the company will earn ($5.41) per share for the year. The consensus estimate for Ikena Oncology's current full-year earnings is ($0.91) per share.
Separately, Wedbush decreased their price objective on Ikena Oncology from $25.00 to $23.00 and set a "neutral" rating on the stock in a research report on Friday, July 25th.
Get Ikena Oncology alerts:
Check Out Our Latest Research Report on IMA
Ikena Oncology Price Performance
NASDAQ IMA opened at $17.90 on Friday. Ikena Oncology has a 1-year low of $11.65 and a 1-year high of $23.28. The business has a 50 day simple moving average of $15.90 and a two-hundred day simple moving average of $15.78. The stock has a market capitalization of $71.96 million, a PE ratio of -2.33 and a beta of 0.50.
Ikena Oncology (NASDAQ:IMA - Get Free Report) last issued its earnings results on Thursday, July 24th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.08.
Institutional Investors Weigh In On Ikena Oncology
A number of hedge funds and other institutional investors have recently bought and sold shares of IMA. BNP Paribas Financial Markets purchased a new position in shares of Ikena Oncology in the fourth quarter worth $72,000. XTX Topco Ltd raised its holdings in shares of Ikena Oncology by 350.6% in the first quarter. XTX Topco Ltd now owns 56,452 shares of the company's stock worth $72,000 after buying an additional 43,924 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Ikena Oncology in the fourth quarter worth $72,000. Northern Trust Corp raised its holdings in shares of Ikena Oncology by 19.7% in the fourth quarter. Northern Trust Corp now owns 57,565 shares of the company's stock worth $94,000 after buying an additional 9,456 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Ikena Oncology by 62.4% in the first quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company's stock worth $98,000 after buying an additional 29,369 shares during the last quarter. Hedge funds and other institutional investors own 75.00% of the company's stock.
Insider Buying and Selling
In other Ikena Oncology news, Director David P. Bonita acquired 83,611 shares of the company's stock in a transaction dated Friday, July 25th. The shares were purchased at an average cost of $29.90 per share, for a total transaction of $2,499,968.90. Following the completion of the purchase, the director owned 287,885 shares in the company, valued at approximately $8,607,761.50. This trade represents a 40.93% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Otello Stampacchia acquired 267,556 shares of the company's stock in a transaction dated Friday, July 25th. The shares were acquired at an average price of $29.90 per share, for a total transaction of $7,999,924.40. Following the completion of the purchase, the director owned 454,982 shares of the company's stock, valued at approximately $13,603,961.80. This represents a 142.75% increase in their position. The disclosure for this purchase can be found here. 5.94% of the stock is currently owned by company insiders.
About Ikena Oncology
(Get Free Report)ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.
See Also
- Five stocks we like better than Ikena Oncology
- How to Start Investing in Real Estate
- Newmont's Financial Strength Sets a High Bar for Gold Miners
- Roth IRA Calculator: Calculate Your Potential Returns
- Golden Cross Alert: 3 Stocks With Serious Upside Potential
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Big Beat, Bigger Plans: AEP Stock Powers Up on Data Center Boom
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Ikena Oncology Right Now?
Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
